Analyst consensus rating
REGENXBIO Analyst Rating: Buy
RGNX is rated Buy by 11 analysts with a $23.73 target. As of 2026-08-31.
Direct answer
REGENXBIO's consensus rating is Buy.
11 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $23.73.
Forecast evidence checked August 31, 2026.
Get free REGENXBIO email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $9.66
- Average price target
- $23.73
- High price target
- $50.00
- Low price target
- $10.00
- Low target gap
- +3.5%
- Target upside
- +145.6%
- High target gap
- +417.6%
- Target range width
- 414.1%
- Consensus rating
- Buy
- Analysts
- 11
- Evidence date
- August 31, 2026
- Valid through
- September 7, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for REGENXBIO?
REGENXBIO has a verified Buy consensus. The same dataset has an average price target of $23.73.
How far are REGENXBIO's low and high targets from the recorded price?
The low target implies +3.5%, while the high target implies +417.6%.
How many analysts are included in REGENXBIO's consensus?
The verified consensus includes 11 analysts.
How is REGENXBIO's target upside or downside calculated?
The average target of $23.73 is divided by the recorded price of $9.66, then one is subtracted to produce +145.6%. This does not guarantee a future return.
When was REGENXBIO's analyst forecast verified?
The data was verified on 2026-08-31. The dataset is valid through 2026-09-07.